 - Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational data - MANIFEST update on pelabresib monotherapy in patients with myelofibrosis - Expanded Real-World RE-MIND2 dataset comparing outcomes for tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T in relapsedrefractory diffuse large B-Cell lymphoma PLANEGGMUNICH, GERMANY ACCESSWIRE November 4, 2021 MorphoSys AG FSE:MORNASDAQ:MOR today announced that new data on approved and clinical-stage therapeutics will be presented during the American Society of Hematology ASH Annual Meeting from December 11-14 in Atlanta, Georgia United States. Ten abstracts were accepted, including two oral presentations, from the comprehensive MorphoSys portfolio, including abstracts for the BET inhibitor pelabresib, which MorphoSys added to its pipeline through the acquisition of Constellation Pharmaceuticals. 